Bionomics to Present at 26th Annual Global Investment Conference
Bionomics to Showcase Innovations at Global Investment Conference
ADELAIDE, Australia, and CAMBRIDGE, Mass. – Bionomics Limited (NASDAQ: BNOX), a pioneering clinical-stage biotechnology firm, is excited to announce its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9 to September 11, 2024, offering both virtual and in-person attendance options.
Presentation Details by CEO
Spyros Papapetropoulos, M.D., Ph.D., who serves as the President and CEO of Bionomics, will be presenting during the conference. Participants can access his presentation on demand beginning September 9 at 7:00 AM ET. This presentation will focus on the company's advancements in developing innovative therapies for severe central nervous system (CNS) disorders.
Opportunities for Engagement
In addition to the presentation, Bionomics' management team will be available for one-on-one meetings throughout the conference. Investors interested in engaging with the team are encouraged to reach out to their representatives at H.C. Wainwright.
Company Overview
Bionomics Limited is at the forefront of developing novel therapeutics that target allosteric ion channels. Their current lead candidate, BNC210, is an oral treatment being prepared to address social anxiety disorder (SAD) and chronic post-traumatic stress disorder (PTSD). Bionomics also partners with Merck & Co., Inc. to advance two early-stage drugs aimed at cognitive impairments associated with Alzheimer's disease and other CNS concerns. With a focus on unmet medical needs, the company's preclinical portfolio includes promising candidates targeting specific ion channels crucial for CNS health.
Contact Information
For further inquiries, please contact:
General:
Rajeev Chandra
Company Secretary
Email: CoSec@bionomics.com.au
Investor Relations:
Kevin Gardner
Email: kgardner@lifesciadvisors.com
Investor Relations:
Chris Calabrese
Email: ccalabrese@lifesciadvisors.com
Frequently Asked Questions
What is Bionomics Limited known for?
Bionomics Limited specializes in developing innovative allosteric ion channel modulators targeting CNS disorders.
When will Bionomics present at the Global Investment Conference?
Dr. Spyros Papapetropoulos will present at the conference, available from September 9, 2024.
How can investors engage with Bionomics during the conference?
Investors can schedule one-on-one meetings with Bionomics' management team through H.C. Wainwright.
What is the lead drug candidate of Bionomics?
BNC210 is the leading candidate aimed at treating social anxiety disorder and PTSD.
Is there any partnership Bionomics is currently engaged in?
Yes, Bionomics has a strategic partnership with Merck & Co., Inc. for developing two drugs in early clinical trials.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Object Management Group Launches New Journal of Innovation
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Fleet Management Software Market Growth to USD 93.17 Billion
- Optical Modulators Market Growth Metrics and Key Drivers
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- Global Cash Handling Device Market Growth Insights
- Nutricosmetics Market Expected to Exceed $16.93 Billion Growth
- Affiliated Network Providers and Aurora Health Join Forces
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Ignitis Group Commits to 174 MW Tume Solar Project
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Plumas Bank Unveils 2024 Corporate Citizenship Insights
Recent Articles
- IR Spectroscopy Market Growth Predictions Highlighted by R&D
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- Vislink Technologies Welcomes Joseph Lipowski as CTO
- Wyoming Rare Inc. Reports Exceptional Drill Results
- Forward Therapeutics Appoints Ulrich Thienel as CMO
- Ruder Finn Appoints Zack Kass to Lead New AI Advisory Council
- Lucid Diagnostics Partners with Front Line Mobile Health
- Nokia's Strategic Fibre Network Deal with AT&T
- PharmaCorp Strengthens Position with New Pharmacy Acquisition
- Altimmune Unveils Pemvidutide Clinical Data at Diabetes Meeting
- Innovative Insights from Cold Spring Harbor Laboratory's Research
- Emergent BioSolutions Enhances Financial Stability with Refinancing
- Viracta Therapeutics to Showcase Innovations at Conference
- Bio-Path Holdings Set to Present at the Global Investment Conference
- Viridien Highlights Total Voting Rights and Share Information
- Blackwell 3D Advances Corporate Growth and Asian Expansion Plans
- Clearlake Capital Expands Global Private Credit with MV Credit Acquisition
- Industrial 3D Printing Market Projected to Reach $88 Billion
- 36Kr Holdings Inc. Announces First Half of 2024 Financial Results
- Warren Buffett's Top Pick: Why Berkshire Hathaway Stands Out
- Clean Motion to Showcase Innovative EVIG at IAA Transportation
- SeeByte and Kraken Robotics Collaborate for Integrated Solutions
- THERAKOS™ CELLEX™ System Secures New EU CE Certification
- Quidax Sets Milestone as Nigeria’s First SEC Licensed Exchange
- Bitcoin ETFs Surge: A New Era for Cryptocurrency Investment